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Transitioning to a national health system in Cyprus: a stakeholder 
analysis of pharmaceutical policy reform
Olivier J Woutersa & Panos G Kanavosa
Introduction
In 2013, Cyprus had a population of about 858 000 and a 
gross domestic product (GDP) of about 16 500 euros (€) per 
capita.1,2 The country’s health system consists of a public and 
a private sector. Individuals with annual incomes of no more 
than €15 400, the chronically ill and civil servants – together 
representing about 83% of the population – are eligible for 
public-sector coverage.3 The government pays for public-
sector health care while patients and private health insurers 
pay for private-sector health care. Total health expenditure is 
about 7.3% of GDP.4 About 43% and 57% of health spending is 
publicly and privately funded, respectively.1 In 2010, pharma-
ceutical expenditure – €322 per capita – accounted for 19.8% 
of total health expenditure in Cyprus.1
In 2013, Cyprus agreed to a memorandum of under-
standing with creditors from the European Commission, 
European Central Bank and International Monetary Fund 
and introduced an economic adjustment programme to 
address the country’s financial, fiscal and structural chal-
lenges.5 The memorandum calls for the introduction of a 
national health system finance reform by mid-2016 to al-
low free choice of provider, social equality and solidarity, 
financial sustainability, and universal coverage of a mini-
mum benefit basket.6 In the forthcoming system, the gov-
ernment will pay for all health-care services in the benefit 
basket – subject to cost sharing – and supplement current 
tax revenues with other sources of funding, including taxes 
on employers, employees and pensioners.7 The reform will 
bring major changes in financing, coverage, provider pay-
ment and data collection and monitoring.3 The government 
still needs to decide which drugs to cover, which pricing 
and reimbursement policies to apply and what type of cost 
sharing to introduce.
Given the lack of research on the Cypriot pharmaceutical 
system,8–12 the aim of this study was to review the current sys-
tem of pharmaceutical care in the private and public sectors in 
terms of the availability and affordability of medicines. We also 
wanted to explore how the public and private markets could 
be efficiently merged in the national health system and to as-
sess the key barriers to the implementation of the new system.
Methods
To collect primary data, we conducted interviews in April 
2014 with senior representatives from seven national organi-
zations (Box 1).13 The interviewees represented all but one of 
the organizations involved in pharmaceutical care in Cyprus. 
The exception was the Cyprus Medical Association, whose 
representatives were unavailable to meet. The interviewees 
were jointly selected by the researchers, the World Health 
Organization Regional Office for Europe and the Cypriot 
Ministry of Health. We met with the representatives from each 
organization separately over three days and each interview 
lasted between 30 minutes and two hours. All interviews were 
held at the headquarters of the health ministry’s Department 
of Pharmaceutical Services, in Nicosia. At least three members 
of this department were present at each interview.
The interviews were semi-structured (Box 2) but the dis-
cussions varied based on the roles of each organization. One of 
the researchers and a ministry of health employee took notes 
during each interview, and these notes were discussed with 
health ministry officials after each meeting, to confirm our un-
derstanding of the data. We followed the consolidated criteria for 
Objective To review the pharmaceutical sector in Cyprus in terms of the availability and affordability of medicines and to explore 
pharmaceutical policy options for the national health system finance reform expected to be introduced in 2016.
Methods We conducted semi-structured interviews in April 2014 with senior representatives from seven key national organizations involved 
in pharmaceutical care. The captured data were coded and analysed using the predetermined themes of pricing, reimbursement, prescribing, 
dispensing and cost sharing. We also examined secondary data provided by the Cypriot Ministry of Health; these data included the prices 
and volumes of prescription medicines in 2013.
Findings We identified several key issues, including high medicine prices, underuse of generic medicines and high out-of-pocket drug 
spending. Most stakeholders recommended that the national government review existing pricing policies to ensure medicines within the 
forthcoming national health system are affordable and available, introduce a national reimbursement system and incentivize the prescribing 
and dispensing of generic medicines. There were disagreements over how to (i) allocate responsibilities to governmental agencies in the 
national health system, (ii) reconcile differences in opinion between stakeholders and (iii) raise awareness among patients, physicians and 
pharmacists about the benefits of greater generic drug use.
Conclusion In Cyprus, if the national health system is going to provide universal health coverage in a sustainable fashion, then the national 
government must address the current issues in the pharmaceutical sector. Importantly, the country will need to increase the market share 
of generic medicines to contain drug spending.
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reporting qualitative research checklist14 
and used NVivo 10 (QSR International, 
Melbourne, Australia) to organize, code 
and analyse the interview data.
The Department of Pharmaceutical 
Services also provided secondary data to 
help us understand the current policies 
and features of the pharmaceutical mar-
kets. These data included the prices and 
volumes of all prescription medicines 
used in the public and private sectors 
in 2013, relevant legislative documents 
and internal ministry of health reports. 
The quantitative data were analysed us-
ing Excel 2007 (Microsoft, Redmond, 
United States of America).
Results
Current pharmaceutical policies
Public sector
Public-sector drugs, which are freely 
available to patients with public health 
insurance, are procured centrally by the 
ministry of health through two types of 
tenders: open invitations and negotia-
tions.10,11
In an open invitation, which is used 
for about 75% of the drugs consumed 
in the public sector, the ministry of 
health issues a request for a quantity 
of drugs and invites confidential bids 
from manufacturers worldwide. The 
manufacturer that offers the lowest 
price is then asked to supply the entire 
market for two years. A tender category 
usually includes a single molecule – i.e. 
the originator brand drug and generic 
drugs with the same active ingredient 
– but may also include all drugs that 
treat the same condition – e.g. the class 
of cholesterol-reducing drugs known 
as statins. The invitation process lasts 
about eight months – excluding drug 
delivery time – and accounted for €54.5 
million of government expenditure in 
2013. The remaining 25% of drugs used 
in the public sector, which are mostly 
on-patent, are procured through nego-
tiations and accounted for €50 million 
of government expenditure in 2013. 
Once a tender price has been accepted 
by both the ministry of health and the 
manufacturer, it is legally binding and 
cannot be changed.
The public-sector tender prices of 
generic drugs are usually 20–70% lower 
than the private-sector wholesale prices. 
In extreme cases, prices in the private 
sector may be more than 30-fold higher 
than in the public sector (Table 1). For 
on-patent drugs, however, the public-
sector prices are usually only 5–10% 
lower than the private-sector prices.
For all tenders, the government 
buys the stock in three to four instal-
ments and distributes the drugs to the 
11 hospital and 34 retail pharmacies 
in Cyprus, which together represent 
one public pharmacy for every 15 500 
public-sector patients. Public-sector 
pharmacists receive a government sal-
ary. The annual storage, distribution and 
dispensing costs for drugs sold in retail 
pharmacies total about €6.3 million.
Table 2 summarizes the drug ex-
penditure in the public sector for the 
year 2013; the 10 and 50 highest-selling 
products accounted for 17.6% and 44.0% 
of expenditure, respectively. In the same 
year, there were 18 foreign research-
based manufacturers that each had 
over €1 million in public-sector drug 
sales in Cyprus – together represent-
ing 56.0% of all such sales. All foreign 
manufacturers sell their drugs in Cyprus 
via about 45 importers. These importers 
serve as wholesalers and handle national 
pharmacovigilance requirements. There 
are three Cypriot generic drug manufac-
turers, which export as much as 93% of 
their output to foreign markets.
All drugs sold in the Cypriot public 
sector are listed in a national formu-
lary, which included 1767 products 
in 2013. Nearly all of the drugs used 
in Cyprus for the treatment of cancer, 
haemophilia, hepatitis B, hepatitis C 
and human immunodeficiency virus are 
sold exclusively in public pharmacies 
because all patients with these illnesses 
are eligible for public coverage. There is a 
co-payment plan, with an annual budget 
of €600 000, that allows public-sector 
patients to buy medicines only available 
in the private sector.
Private sector
Private-sector drug prices are set by the 
health ministry based on the recommen-
dations of a pricing committee. For on-
patent products, this committee bases 
the Cypriot wholesale price on the mean 
of the wholesale prices in one high-price 
country – i.e. Sweden, two medium-
price countries – i.e. Austria and France, 
and one low-price country – i.e. Greece. 
If a medicine is not available in one of 
these countries, the committee uses the 
price in a pre-selected alternate country. 
To account for the cost of importing 
the drug into Cyprus, the committee 
adds a 3% mark-up to the derived mean 
price. The committee recalculates the 
prices of most drugs every two years. It 
revises the price of each newly launched 
product annually for the first two years. 
The private-sector prices in Cyprus are 
among the highest in Europe,15 largely 
because this pricing system captures the 
official prices in the reference countries 
Box 1. National organizations represented by interviewees, Cyprus, 2014
•	 Cyprus Association of Pharmaceutical Companies, representing Cypriot drug importers 
and distributors.
•	 Cyprus Association of Research and Development Pharmaceutical Companies, representing 
research-based manufacturers.
•	 Cyprus Pharmaceutical and Chemical Manufacturing Company, representing Cypriot 
manufacturers of generic drugs.
•	 Cyprus Pharmaceutical Manufacturer Association, representing Cypriot pharmacists.
•	 The Health Insurance Organization, the government agency in charge of implementing 
the national health system reforms.
•	 Pancyprian Federation of Patients Associations and Friends, representing Cypriot patients.
•	 Ministry of health’s Department of Pharmaceutical Services, the government department 
in charge of national pharmaceutical policies.
Box 2. Semi-structured interview template used to assess the Cypriot pharmaceutical 
market, Cyprus, 2014
•	 What are the strengths and weaknesses of the pharmaceutical policies in the public sector?
•	 What are the strengths and weaknesses of the pharmaceutical policies in the private sector?
•	 Which pharmaceutical policies should be changed before the introduction of the national 
health system reforms?
•	 Which pharmaceutical policies should be applied in the national health system?
•	 What are the key barriers to the successful implementation of the national health system 
reforms?
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and does not take into account confi-
dential discounts.
After patent expiry, originator 
brand drugs continue to be priced 
through international price referencing. 
Generic drugs must be priced at least 
20% below the price of the originator 
brand at the time of patent expiry. Con-
sumption of generic drugs in the private 
sector is low, partly because pharmacists 
are forbidden by law to substitute such 
drugs for any originator brand drugs 
prescribed by physicians (Box 3).
In 2013 there were 481 private 
pharmacies in Cyprus – i.e. about one 
for every 300 private-sector patients. The 
pharmacy price of a drug includes the 
pharmacist’s mark-up and a value added 
tax of 5%. The mark-up is determined by 
the wholesale price of the drug pack and 
is set at 37%, 33% and 25% for packs that 
cost no more than €50, between €50 and 
€250, and more than €250, respectively. 
Private-sector pharmacists also charge a 
flat fee of €1.00 per prescription.
Table 2 summarizes the 2013 drug 
expenditure in the private sector. The 
10 and 50 highest-selling products ac-
counted for 11.5% and 34.5% of private 
drug spending, respectively. About 87% 
of the total health expenditure within 
the Cypriot private sector was out-of-
pocket while private health insurers 
paid the rest.4 Only 2054 of the 5241 
products registered for sale in the private 
sector were available in 2013 – mostly 
because of insufficient demand for the 
other products.
Policy options
We investigated pharmaceutical policy 
options for the national health system, 
dividing the main feedback and sug-
gestions of the stakeholders into the 
categories of pricing, reimbursement, 
prescribing, dispensing and cost shar-
ing. Below, to contextualize the stake-
holders’ statements, we have added 
references to relevant studies.
Pricing
The consensus was that reviewing the 
current pricing policies to facilitate the 
transition to the national health system 
was important. To decrease the prices 
of on-patent drugs in the public sector, 
the association representing research-
based manufacturers recommended the 
ministry of health keep price discounts 
confidential – thus limiting the spill-
over effect on markets that use Cypriot 
prices for reference. The health ministry 
representatives agreed to investigate 
legal options that could be followed to 
strike confidential agreements on drug 
prices. To reduce private-sector prices, 
the ministry of health offered to adjust 
its system of international price refer-
encing – e.g. it could apply the lowest 
price paid in the reference countries.
Stakeholders held differing views 
about which pricing policy to follow. The 
national associations for drug importers, 
local generic drug manufacturers, phar-
macists and research-based manufactur-
ers each noted that there is a possible 
trade-off between low prices and the 
availability of medicines. As Cyprus is a 
Table 1. Anonymized tender results for three selected medicines, Cyprus, 2013
Product, condition, bid Quantity, 
packs
Bid price, 
€/pack
Budget 
impact, €a
Private-sector 
wholesale 
price, €/pack
Product A (hypertension)
Bid 1 (winner) 36 000 000 0.0189 678 857 0.35
Bid 2 0.0223 804 000
Bid 3 0.0225 801 000
Bid 4 0.0239 861 428
Bid 5 0.0260 936 000
Bid 6 0.0333 1 200 000
Bid 7 0.0411 1 478 571
Bid 8 0.0463 1 668 215
Bid 9 0.1500 5 399 999
Product B (osteoporosis and 
other bone disease)
Bid 1 (winner) 5 000 12.00 60 000 208.02
Bid 2 29.29 146 450
Bid 3 29.50 147 500
Bid 4 29.85 149 250
Bid 5 33.97 169 850
Bid 6 38.90 194 500
Bid 7 50.09 250 439
Bid 8 105.00 525 000
Bid 9 129.00 645 000
Product C (colorectal cancer)
Bid 1 (winner) 2 800 9.12 25 536 50.00
Bid 2 12.00 33 600
€: euros.
a  Actual budget impact may vary due to rounding.
Source: Data provided by the Department of Pharmaceutical Services, Ministry of Health, Nicosia, Cyprus.
Table 2. Drug expenditure in the public and private sectors, Cyprus, 2013
Category Expenditure (millions of euros)a
Public sector Private sector
Prescription drugsb 98.5 80.6
Inpatient 59.5 9.7
Outpatient 39.0 70.9
   On-patent originator brand 7.7 8.4
   Off-patent originator brand 10.8 46.6
   Generic 19.3 11.4
   Vaccines and others 1.2 4.5
Over-the-counter drugs 5.0 14.3
Total drug expenditure 103.5 94.9
a  Excluding value added tax.
b  Inpatient and outpatient drugs are sold in hospital and retail pharmacies, respectively.
Source: Data provided by the Department of Pharmaceutical Services, Ministry of Health, Nicosia, Cyprus.
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small market, these groups posited that, 
if prices drop too low, the manufacturers 
of originator brand and generic drugs 
might not sell their products in Cyprus 
– because it would produce insufficient 
returns on the manufacturers’ invest-
ments and/or adversely affect prices in 
other markets that use Cypriot prices 
for reference. The same groups urged 
the Cypriot government to use inter-
national price referencing in any future 
national health system and to apply a 
reimbursement system to receive con-
fidential discounts. Other things being 
equal, however, a small population size 
does not appear to be associated with 
a relatively low market penetration by 
generic drugs.16
The ministry of health claimed the 
current wholesale prices of drugs in the 
private sector would be unaffordable 
in a national health system and that 
tendering could be used more widely. 
The Health Insurance Organization 
suggested the prices of drugs in the 
national health system should be set 
somewhere between the current public- 
and private-sector prices, but did not 
elaborate further.
Reimbursement
All stakeholders were in favour of in-
troducing a national reimbursement 
system. The Health Insurance Organiza-
tion intends to create a new national for-
mulary and a reimbursement committee 
to manage it. Formularies can be used to 
specify the medicines eligible for reim-
bursement and – alongside prescribing 
guidelines – encourage the rational use 
of medicines.17
The Health Insurance Organization 
and ministry of health are working inde-
pendently on criteria for the admission 
of new products to a future formulary. 
The ministry of health suggested that, 
to guide the inclusion or non-inclusion 
of drugs in a national formulary, the 
government should monitor, collect 
and analyse all relevant clinical and eco-
nomic evidence from health technology 
assessment bodies in other countries. 
The government could ask manufactur-
ers to adapt foreign data on the cost–ef-
fectiveness of drugs to local conditions.
The association for research-based 
manufacturers favoured the use of risk-
sharing schemes in the national health 
system. Such schemes could be applied 
to hedge against uncertainties – at the 
time of a drug’s entry to the Cypriot 
market – regarding the drug’s budget 
impact, clinical effectiveness and cost–ef-
fectiveness. These schemes grant manu-
facturers favourable reimbursement 
rates in return for achieving financial or 
outcome targets. The Health Insurance 
Organization is considering the use of 
risk-sharing schemes. Although such 
schemes are widely used in Europe, they 
require appropriate performance mea-
surement and enforcement.18,19
Finally, the Health Insurance Orga-
nization noted that widespread tendering 
in a unified national market could create 
supply disruptions, drive some generic 
drug manufacturers out of business and 
lead to higher generic drug prices over 
time. The organization proposed instead 
to use internal reference pricing and to 
tender selectively if such pricing does 
not achieve adequate price reductions for 
some products. Internal reference pric-
ing sets a reimbursement ceiling based 
on the prices in a basket of drugs – e.g. 
the mean price of all drugs with the same 
active ingredient. If the price of a drug 
exceeds the reference price, the patient 
usually has to pay the difference. Sys-
tematic reviews have consistently found 
that such a policy can reduce drug prices 
and generate savings.20–22 The federation 
representing patients supported offering 
patients the choice between a generic 
drug and an originator brand version at 
a higher price.
Prescribing
Prescribing guidelines can have a ben-
eficial impact on prescribing, when 
enforced appropriately.23,24 The Cypriot 
Ministry of Health plans to develop such 
guidelines for conditions with a high 
budget impact. When appropriate, the 
ministry might adapt guidelines pub-
lished in other countries.
The interviewed representatives 
of the ministry of health, the Health 
Insurance Organization and pharmacy 
association suggested the government 
enforce the prescribing of generic drugs 
in the national health system. The Health 
Insurance Organization aims to intro-
duce an electronic prescribing system 
to examine prescribing patterns and to 
improve the quality of medicine use. The 
organization is reviewing other options 
to encourage cost–effective prescribing, 
such as pay-for-performance schemes. 
It remains unclear, from the evidence 
collected in other countries, whether 
pay-for-performance schemes often 
achieve their intended goals.25
The Cypriot Ministry of Health be-
lieves there should be appropriate limits 
on drug advertising and on the gifts 
and contributions given to physicians 
by drug manufacturers. One survey 
has found that, for Cypriot physicians, 
pharmaceutical sales representatives are 
one of the most important sources of 
information on the safety and efficacy 
of medicines.26
Dispensing
In some countries, if a physician pre-
scribes an originator brand drug despite 
the availability of a cheaper generic 
equivalent, pharmacists can override 
the physician’s decision and dispense 
the generic drug instead. Depending on 
the country, such generic substitution 
can be mandatory,27 voluntary28 or, as 
in Cyprus, forbidden. In our interviews, 
both the ministry of health and the 
Health Insurance Organization favoured 
mandatory generic substitution, which 
can speed up the market entry of ge-
Box 3. Current issues in the Cypriot pharmaceutical market
•	 The private-sector prices are among the highest in Europe, largely because international 
price referencing does not capture confidential discounts in other countries.
•	 On-patent drugs in the public sector are expensive. As public-sector prices are published 
online – and may therefore influence prices in countries that use the Cypriot prices for 
reference – manufacturers are not willing to provide large discounts to the ministry of health. 
The national association for research-based manufacturers has confirmed this observation.
•	 There is underuse of generic drugs in the private sector and generic substitution by 
pharmacists is forbidden. Over 77% of spending in private retail pharmacies is on branded 
products – i.e. on-patent and off-patent originator brands.
•	 Although there is a national list of approved pharmaceutical products, the government 
does not disseminate any prescribing guidelines and there are no information systems to 
monitor or control prescribing behaviour.
•	 There are few limits on the financial relationships between physicians and manufacturers, 
which may lead to conflicts of interest.
•	 Private-sector patients pay for drugs almost entirely out-of-pocket. This could expose patients 
to undue financial risks or deter some from seeking beneficial treatment.
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neric drugs and reduce pharmaceutical 
spending.29 The federation representing 
patients opposed such substitution, 
however, and stated that all treatment 
decisions should be made by physicians.
Most (81.3%) sales in the Cypriot 
private sector in 2013 were for drug 
packs with a wholesale price of no more 
than €50 per pack – these packs were 
subject to one of the highest pharmacy 
mark-ups in Europe, of 37%.30 The min-
istry of health and the Health Insurance 
Organization stressed that pharmacy 
mark-ups needed to be reduced and 
revised in Cyprus to encourage the 
dispensing of generic drugs. However, 
the interviewees from the association 
representing pharmacists expressed 
concern about the poor macroeconomic 
conditions in Cyprus and, consequently, 
the financial viability of pharmacies if 
the remuneration system were to change 
in any way that would reduce the income 
of pharmacists.
Cost sharing
The Health Insurance Organization is 
exploring various cost-sharing options 
– i.e. deductibles, co-insurance or co-
payments or any combination of these. 
The organization is also considering 
whether to apply exemption criteria 
and cost-sharing caps to protect patients 
financially. It may remove co-payments 
for conditions where compliance is an 
issue, such as some psychiatric condi-
tions. The interviewees from the fed-
eration representing patients stressed 
the importance of limits on cost shar-
ing to protect vulnerable groups like 
the chronically ill. The interviewees 
from the ministry of health stated that 
the current out-of-pocket burden on 
private-sector patients was too high and 
that this burden needed to be reduced 
in the national health system.
Barriers
We identified four key barriers to the 
successful implementation of a compre-
hensive drug-benefit plan in the forth-
coming national health system reforms.
First, it appeared difficult to obtain 
the buy-in of all stakeholders for the 
health-care reform. Notably, there was 
disagreement over whether the prices of 
prescription medicines in the future sys-
tem should be the current private-sector 
or public-sector prices or lie somewhere 
between the two. Other disputes might 
arise, such as physicians resisting the 
monitoring of prescribing habits. To 
resolve such disputes, it is important to 
involve all stakeholders in the reform 
process.
Second, the governmental stake-
holders – i.e. the Health Insurance Or-
ganization and ministry of health – need 
to clarify their roles in the forthcoming 
system, particularly regarding who will 
be in charge of reimbursement. Clear 
and transparent rules are needed to 
allocate responsibilities. Since its in-
ception, the Cypriot Ministry of Health 
has been solely in charge of national 
pharmaceutical policies. Although the 
Health Insurance Organization was 
established in 2001,7 it has only been 
actively engaged in discussions with the 
ministry of health for the last few years.
Third, most of the proposed policy 
changes would need to be accompanied 
by legislative changes, which may be 
time-consuming. Although the memo-
randum of understanding provided a 
broad timeline for the implementation 
of a national health system – including 
deadlines for key legislative changes 
– it allowed little time for consensus-
building and preparation.
Finally, the Pancyprian Federation 
of Patients Associations and Friends 
stated that many patients – especially 
in the private sector – do not perceive 
generic drugs to be as good as the origi-
nator brand drugs in terms of safety and 
efficacy. It is possible that in Cyprus 
some physicians and pharmacists also 
exhibit loyalty to originator brand 
medicines. Such perceptions and brand 
loyalty have been observed elsewhere31,32 
and may explain why generic substitu-
tion has been forbidden in the Cypriot 
private sector. The government could 
launch a public education campaign to 
promote the use of generic drugs.33
Discussion
Pharmaceutical policies should reflect 
national priorities for health and in-
dustrial policy, including cost contain-
ment, employment, innovation and 
trade promotion.34 In many countries, 
the main objectives of pharmaceutical 
policies are to ensure equitable access 
to – and the good quality and rational 
use of – effective drugs.35 The findings of 
this study are meant to inform the ongo-
ing policy deliberations in Cyprus. They 
can also be used to inform discussions 
in other countries aiming to establish a 
comprehensive drug-benefit plan under 
universal health coverage.
This study has some limitations. 
First, personal bias is unavoidable in 
interviews. To minimize the risk of such 
bias, both interviewers closely followed 
an interview template. Second, no rep-
resentatives of the Cyprus Medical As-
sociation were available for an interview 
during the study visit. Members of this 
association could have provided valu-
able input on the prescribing environ-
ment. Finally, although this study looked 
at reform in the pharmaceutical sector, a 
holistic analysis is needed to understand 
the full impact of national health system 
reforms in Cyprus.
Over the next few years, there is a 
need to update the legislative and insti-
tutional framework in Cyprus and to 
acquire data, through pilot studies and 
simulations, on how health care might 
operate under the new system. There is 
a further need to build capacity and to 
address issues before and after reforms 
are introduced. The government should 
work to eliminate each of the four bar-
riers identified. The Cypriot authorities 
should also prepare for unforeseen 
problems that inevitably accompany 
large-scale changes to health systems. 
Once new policies are implemented, the 
government should continue to monitor 
the results. ■
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صخلم
ةيئاودلا ةسايسلا حلاصلإ ةينعلما تاهلجا روظنم نم ليلتح :صبرق في ينطو يحص ماظن لىإ لاقتنلاا
 ةيودلأا رفوت ثيح نم صبرق في يئاودلا عاطقلا ةعجارم ضرغلا
 ةحاتلما ةيئاودلا ةسايسلا تارايخ فاشكتساو ،اهراعسأ ةيلوقعمو
 في هذيفنت  عمزلما  ينطولا  يحصلا  ماظنلل  ةيلالما  بناولجا  حلاصلإ
.2016 ماع
 ماع  نم  ناسين/ليربأ  في  ةننقم  هبش  تلاباقم  انيرجأ  ةقيرطلا
 في كراشت ةزراب ةينطو تاسسؤم عبس نم ينلثملما رابك عم 2014
 مادختساب اهليلتحو ةلّجسلما تانايبلا  يرفشت متو .ةيئاودلا  ةياعرلا
 فيلاكتلا  درو  يرعستلاب  ةقلعتلماو  اًفلس  ةددحلما  تاعوضولما
 انرظن ماك .ةفلكتلا في ةكراشلماو ةيودلأا فصرو ءابطلأا تافصوو
 دقو ،ةيصبرقلا ةحصلا ةرازو اهتمدق يتلا ةيوناثلا تانايبلا في اًضيأ
 اتهايمكو ءابطلأا اهفصي يتلا ةيودلأا راعسأ تانايبلا هذه تنمضت
.2013 ماع في
 راعسلأا  لمشي  ماب  ،ةيساسأ  تلاكشم  ةدع  انددح  دقل  جئاتنلا
 مجحو  ،ةئفاكلما  ةيودلأاب  فياكلا  عافتنلاا  مدعو  ،ءاودلل  ةعفترلما
 تصوأ  دقو  .ة�يودلأا  لىع  ضىرلما  بناج  نم  عفترلما  قافنلإا
 تاسايس ةعجارم ةينطولا ةموكلحا لىوتت نأب ةينعلما تاهلجا بلغأ
 ماظنلا  راطإ  في  ةمدقلما  ةيودلأا  نوكت  نأ  نماضل  ةمئاقلا  يرعستلا
 ينطو ماظن حرطو ،ةلوقعم ةفلكتبو ةرفوتم ِلبقُلما ينطولا يحصلا
 ةئفاكلما ةيودلأا فصو لىع ةعجشلما زفاولحا ميدقتو ،فيلاكتلا درل
 تايلوؤسلما دانسإ )أ( ةيفيك لوح تافلاخ تأشن دقو .اهفصرو
 ينب قيفوتلا )ب(و ،ينطولا يحصلا ماظنلا في ةيموكلحا تاهجلل
 ةجرد  عفر  )�ج(و  ،ةينعلما  تاهلجا  ينب  ام  ءارلآا  في  تافلاتخلاا
 ةدايزب ةطبترلما عفانلما نأشب ةلدايصلاو ءابطلأاو ضىرلما ينب يعولا
.ةئفاكلما ةيودلأاب عافتنلاا
 ميدقت مزتعي صبرق في ينطولا  يحصلا ماظنلا  ناك اذإ  جاتنتسلاا
 نأ  ةينطولا  ةموكلحا  لىعف  ،ةمادتسم  ةقيرطب  ةماع  ةيحص  ةيطغت
 هنأ  وه  مهلأاو  .يئاودلا  عاطقلا  في  ةيلالحا  تلاكشلما  عم  لماعتت
 ةئفاكلما  ةيودلأل ةحونملما  قوسلا  ةصح ةدايز صبرق لىع ينعتيس
.ةيودلأا لىع قافنلإا لمشتل
摘要
在塞浦路斯过渡至国家卫生系统 ： 医药政策改革的利益相关者分析
目的 旨在评审塞浦路斯境内医药部门的药品可用性和
可负担性，并且针对有望在 2016 年引进的国家卫生系
统财政改革探讨医药政策选择。
方法 我们与参与医药保健的七个主要国家组织的高级
代表一起在 2014 年 4 月开展了一项半结构性访谈。 
通过采用定价、报销、开处方、配药和成本分担这些
预先设定的主题，我们对所获取的数据进行了编码和
分析。 我们还研究了由塞浦路斯卫生部提供的次级数
据 ；在 2013 年的处方药价格及销量中包含这些数据。
结果 我们确定了几个关键问题，包括药品价格高、非
专利药品未得到充分利用，以及自费药品支出高。 大
多数利益相关者建议国家政府应评审现有价格政策，
以确保药品在即将设立的国家卫生系统中具有可负担
性和可用性，同时应引进国家报销系统，并且采取奖
励措施以鼓励在开方和配药时采用非专利药品。 以下
几点存在分歧 ：(i) 如何分配政府机构在国家卫生系统
中承担的责任，(ii) 如何使利益相关者之间的看法差
异达成一致，以及 (iii) 如何使患者、医师和药剂师在
更加广泛地使用非专利药品方面提高意识。
结论 在塞浦路斯，如果国家卫生系统要以可持续发展
的方式提供全民医疗保险，那么国家政府就必须解决
医药部门目前出现的问题。 重要的是，该国将需提高
非专利药品的市场份额，以遏制药品支出。
Résumé
Transition vers un nouveau système de santé national à Chypre: analyse par les parties prenantes de la réforme des politiques 
pharmaceutiques
Objectif Examiner le secteur pharmaceutique à Chypre en termes de 
disponibilité et d’accessibilité économique des médicaments et étudier 
les options de politiques pharmaceutiques envisageables pour la réforme 
du financement du système de santé national, prévue pour 2016.
Méthodes Nous avons réalisé des entretiens semi-directifs en avril 2014 
auprès de responsables représentant sept organisations nationales clés 
impliquées dans les soins pharmaceutiques. Les données obtenues 
ont été codées et analysées en utilisant les thèmes prédéfinis suivants: 
tarification, remboursement, prescription, délivrance et participation aux 
coûts. Nous avons également étudié des données secondaires fournies 
par le Ministère de la Santé chypriote; des données qui incluaient les 
prix et volumes des médicaments délivrés sur ordonnance en 2013.
Résultats Nous avons identifié plusieurs problèmes essentiels, 
notamment les prix élevés des médicaments, une sous-utilisation des 
médicaments génériques et des débours directs importants. La plupart 
des parties prenantes ont recommandé que le gouvernement national 
revoie les politiques de tarification existantes pour que les médicaments 
soient disponibles et économiquement accessibles dans le nouveau 
système de santé, qu’il mette en place un système de remboursement 
national et qu’il incite à prescrire et à délivrer des médicaments 
génériques. Des désaccords sont apparus sur la manière (i) d’affecter les 
responsabilités entre les différents organismes gouvernementaux dans 
le nouveau système de santé national, (ii) de réconcilier les divergences 
d’opinions des parties prenantes et (iii) de sensibiliser les patients, les 
médecins prescripteurs et les pharmaciens sur les avantages d’une plus 
grande utilisation des médicaments génériques.
Conclusion À Chypre, si l’on veut que le nouveau système national de 
santé garantisse une couverture sanitaire universelle de manière durable, 
il faudra d’abord que le gouvernement national résolve les problèmes 
qui existent actuellement dans le secteur pharmaceutique. Un élément 
déterminant consistera à augmenter la part de marché des médicaments 
génériques afin de contenir les dépenses en médicaments. 
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Резюме
Переход к национальной системе здравоохранения на Кипре: партнерский анализ реформы 
фармацевтической политики
Цель Рассмотреть состояние фармацевтического сектора 
на Кипре с точки зрения доступности медикаментов по 
ассортименту и цене и изучить возможности фармацевтической 
политики в плане реформы финансирования национальной 
системы здравоохранения, которая, как ожидается, будет 
проведена в 2016 г.
Методы В апреле 2014 г.  были проведены частично 
структурированные опросы представителей высшего 
руководства семи основных национальных организаций, 
вовлеченных в оказание лекарственной помощи населению. 
Собранные данные были переведены в цифровой формат и 
проанализированы с точки зрения заранее определенных 
аспектов: ценообразования, возмещения, выдачи рецептов, 
отпуска и распределения затрат. Мы также изучили вторичные 
данные, предоставленные Министерством здравоохранения 
Кипра, которые включали сведения о ценах и количестве 
рецептурных препаратов, выписанных в 2013 г.
Результаты Были выявлены несколько основных проблем, 
включая высокие цены на лекарства, недостаточное 
использование дженериков и слишком частое использование 
собственных средств на оплату лекарств. Большинство партнеров 
предложили национальному правительству пересмотреть 
существующую политику ценообразования, чтобы в будущей 
системе здравоохранения лекарства были более доступны 
по цене и ассортименту, ввести национальную систему 
возмещения затрат на медикаменты и поощрять назначение и 
отпуск дженериков. Имелись разногласия по поводу того, как 
(i) распределить ответственность между правительственными 
органами в национальной системе здравоохранения, (ii) 
примирить разногласия во мнениях между партнерами и 
(iii) предоставить пациентам, врачам и фармацевтам больше 
информации о пользе дженериков.
Вывод Если национальная система здравоохранения на Кипре 
намерена стабильно предоставлять населению общедоступные 
услуги по охране здоровья, национальному правительству следует 
обратить внимание на текущие проблемы фармацевтического 
сектора. Важно, что страна должна будет увеличить рыночную 
долю дженериков, чтобы уменьшить затраты на медицинские 
препараты.
Resumen
La transición a un sistema nacional de salud en Chipre: un análisis de los interesados en la reforma de la política farmacéutica
Objetivo Revisar el sector farmacéutico en Chipre en términos de 
la disponibilidad y asequibilidad de los medicamentos y explorar las 
opciones de la política farmacéutica para la reforma financiera del 
sistema nacional de salud que se prevé introducir en 2016.
Métodos En abril de 2014 se llevaron a cabo entrevistas semiestructuradas 
con los principales representantes de siete organizaciones nacionales 
clave involucradas en la atención farmacéutica. Se cifraron los datos 
obtenidos y se analizaron utilizando los temas predeterminados de 
fijación de precios, reembolso, prescripción, dispensación y reparto de 
costes. También se examinaron los datos secundarios proporcionados 
por el Ministerio de Salud de Chipre, los cuales incluían el precio y el 
volumen de los medicamentos recetados en 2013.
Resultados Se identificaron varias cuestiones clave, entre las que se 
incluyen el alto precio de los medicamentos, la poca utilización de 
medicamentos genéricos y el alto gasto en el desembolso de fármacos. 
La mayoría de los interesados recomendaron que el gobierno nacional 
revisara las políticas de fijación de precios existentes para asegurar 
que los medicamentos dentro del inminente sistema nacional de 
salud fuesen accesibles y asequibles, que introdujera un sistema de 
reembolso nacional y que incentivara la prescripción y distribución 
de medicamentos genéricos. Hubo desacuerdos en cuanto al modo 
de (i) asignar responsabilidades a las agencias gubernamentales en el 
sistema nacional de salud, (ii) resolver las diferencias de opinión entre los 
interesados y (iii) fomentar la sensibilización en cuanto a los beneficios 
de un mejor uso de los fármacos genéricos entre los pacientes, médicos 
y farmacéuticos.
Conclusión En Chipre, si el sistema nacional de salud quiere 
proporcionar cobertura sanitaria universal de un modo sostenible, 
el gobierno nacional tendrá que tratar los problemas actuales del 
sector farmacéutico. Otro aspecto importante es que el país necesitará 
aumentar la cuota de mercado de los medicamentos genéricos si quiere 
contener el gasto en fármacos.
References
1. Eurostat: your key to European statistics [Internet]. Luxembourg: European 
Commission; 2014. Available from: http://epp.eurostat.ec.europa.eu/ [cited 
2014 Oct 3]. 
2. Demographic report, 2013 [Internet]. Nicosia: Ministry of Finance; 2014. 
Available from: http://www.mof.gov.cy/mof/cystat/statistics.nsf/All/D1D14
1B22F756140C2257DB3003B1A44?OpenDocument&sub=1&sel=1&e=&pri
nt [cited 2015 Jun 2].
3. Cylus J, Papanicolas I, Constantinou E, Theodorou M. Moving forward: 
lessons for Cyprus as it implements its health insurance scheme. 
Health Policy. 2013 Apr;110(1):1–5. doi: http://dx.doi.org/10.1016/j.
healthpol.2012.12.007 PMID: 23295160
4. Open data [Internet]. Washington: World Bank; 2014. Available from: http://
data.worldbank.org/ [cited 2015 May 18].
5. Economic adjustment programme for Cyprus [Internet]. Brussels: European 
Commission; 2014. Available from: http://ec.europa.eu/economy_finance/
assistance_eu_ms/cyprus/index_en.htm [cited 2014 Oct 9].
6. Memorandum of understanding on specific economic policy conditionality. 
Nicosia: Ministry of Finance; 2014. Available from: http://www.mof.gov.
cy/mof/mof.nsf/Revised%20Memorandum%20of%20Understanding%20
September%202014.pdf [cited 2015 May 18].
7. The General Health Care Scheme Law of 2001 (N.89(I)/2001). Nicosia: Law 
Commissioner’s Office; 2001. Available from: http://www.hio.org.cy/docs/
nomos%20gesy%20english.pdf [cited 2015 May 18].
8. Petrou P. Pharmacoeconomics in the years of crisis: a solution or just a 
resolution? A Cyprus perspective. Expert Rev Pharmacoecon Outcomes Res. 
2014 Oct;14(5):627–36. doi: http://dx.doi.org/10.1586/14737167.2014.9179
69 PMID: 24953125
9. Petrou P, Talias MA. A pilot study to assess feasibility of value based pricing 
in Cyprus through pharmacoeconomic modelling and assessment of its 
operational framework: sorafenib for second line renal cell cancer. Cost Eff 
Resour Alloc. 2014;12(1):12. doi: http://dx.doi.org/10.1186/1478-7547-12-12 
PMID: 24910539
Bull World Health Organ 2015;93:606–613| doi: http://dx.doi.org/10.2471/BLT.14.148742 613
Research
Pharmaceutical policy reform in CyprusOlivier J Wouters & Panos G Kanavos
10. Petrou P. The power of r – pharmaceutical sales decomposition in Cyprus 
public healthcare sector and determinants of drug expenditure evolution: 
any lessons learned? Expert Rev Pharmacoecon Outcomes Res. 2014 
Apr;14(2):289–300. doi: http://dx.doi.org/10.1586/14737167.2014.889565 
PMID: 24580120
11. Petrou P, Talias M. Tendering for pharmaceuticals as a reimbursement tool 
in Cyprus public health sector. Health Policy Technol. 2014;3(3):167–75. doi: 
http://dx.doi.org/10.1016/j.hlpt.2014.04.003
12. Petrou P, Vandoros S. Cyprus in crisis: recent changes in the pharmaceutical 
market and options for further reforms without sacrificing access to or 
quality of treatment. Health Policy. 2015 May;119(5):563–8. doi: http://
dx.doi.org/10.1016/j.healthpol.2015.03.004 PMID: 25837234
13. Kanavos P, Wouters O. Pharmaceutical policies in Cyprus: a review of the 
current system and future options. Nicosia: Ministry of Health; 2014.
14. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups. Int 
J Qual Health Care. 2007 Dec;19(6):349–57. doi: http://dx.doi.org/10.1093/
intqhc/mzm042 PMID: 17872937
15. Merkur S, Mossialos E. A pricing policy towards the sourcing of cheaper 
drugs in Cyprus. Health Policy. 2007 May;81(2-3):368–75. doi: http://dx.doi.
org/10.1016/j.healthpol.2006.07.007 PMID: 16949176
16. Kanavos P. Measuring performance in off-patent drug markets: a 
methodological framework and empirical evidence from twelve EU 
Member States. Health Policy. 2014 Nov;118(2):229–41. doi: http://dx.doi.
org/10.1016/j.healthpol.2014.08.005 PMID: 25201433
17. Gilman BH, Kautter J. Consumer response to dual incentives under 
multitiered prescription drug formularies. Am J Manag Care. 2007 Jun;13(6 
Pt 2):353–9. PMID: 17567236
18. Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing 
arrangements that link payment for drugs to health outcomes are proving 
hard to implement. Health Aff (Millwood). 2011 Dec;30(12):2329–37. doi: 
http://dx.doi.org/10.1377/hlthaff.2010.1147 PMID: 22147861
19. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new 
medicines: a comparative analysis of the use of managed entry agreements 
in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015 
Jan;124:39–47. doi: http://dx.doi.org/10.1016/j.socscimed.2014.11.003 
PMID: 25461860
20. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference 
pricing. Health Policy. 2000 Nov 17;54(2):87–123. doi: http://dx.doi.
org/10.1016/S0168-8510(00)00100-7 PMID: 11094265
21. Puig-Junoy J. Impact of European pharmaceutical price regulation on 
generic price competition: a review. Pharmacoeconomics. 2010;28(8):649–
63. doi: http://dx.doi.org/10.2165/11535360-000000000-00000 PMID: 
20515079
22. Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in 
pharmaceutical markets: a review. Pharmacoeconomics. 2011 Jan;29(1):17–
33. doi: http://dx.doi.org/10.2165/11537860-000000000-00000 PMID: 
21142276
23. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. 
Interventions to improve antibiotic prescribing practices for hospital 
inpatients. Cochrane Database Syst Rev. 2013;4:CD003543. PMID: 23633313
24. Zachariadou T, Stoffers HE, Christophi CA, Philalithis A, Lionis C. 
Implementing the European guidelines for cardiovascular disease 
prevention in the primary care setting in Cyprus: lessons learned from a 
health care services study. BMC Health Serv Res. 2008;8(1):148. doi: http://
dx.doi.org/10.1186/1472-6963-8-148 PMID: 18631389
25. James J. Health policy brief: pay-for-performance. Maryland: Health Affairs; 
2012. Available from: http://healthaffairs.org/healthpolicybriefs/brief_pdfs/
healthpolicybrief_78.pdf [cited 2015 Jun 2]. 
26. Theodorou M, Tsiantou V, Pavlakis A, Maniadakis N, Fragoulakis V, Pavi E, 
et al. Factors influencing prescribing behaviour of physicians in Greece 
and Cyprus: results from a questionnaire based survey. BMC Health Serv 
Res. 2009;9(1):150. doi: http://dx.doi.org/10.1186/1472-6963-9-150 PMID: 
19695079
27. Andersson KA, Petzold MG, Allebeck P, Carlsten A. Influence of mandatory 
generic substitution on pharmaceutical sales patterns: a national study 
over five years. BMC Health Serv Res. 2008;8(1):50. doi: http://dx.doi.
org/10.1186/1472-6963-8-50 PMID: 18312635
28. Simeons S, De Coster S. Sustaining generic medicines markets in Europe. 
Leuven: Research Centre for Pharmaceutical Care and Pharmacoeconomics, 
Katholieke Universiteit; 2006.
29. Pharmaceutical sector inquiry - final report. Brussels: European 
Commission; 2009.
30. Kanavos P, Schurer W, Vogler S. The pharmaceutical distribution chain in the 
European Union: structure and impact on pharmaceutical prices. Brussels: 
European Commission; 2011.
31. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry 
NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011 
Jan;45(1):31–8. doi: http://dx.doi.org/10.1345/aph.1P389 PMID: 21205953
32. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions 
of generic medications. Health Aff (Millwood). 2009 Mar-Apr;28(2):546–56. 
doi: http://dx.doi.org/10.1377/hlthaff.28.2.546 PMID: 19276015
33. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use 
of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes 
Res. 2013 Feb;13(1):59–72. doi: http://dx.doi.org/10.1586/erp.12.83 PMID: 
23402447
34. Wagner AK, Quick JD, Ross-Degnan D. Quality use of medicines within 
universal health coverage: challenges and opportunities. BMC Health Serv 
Res. 2014;14(1):357. doi: http://dx.doi.org/10.1186/1472-6963-14-357 PMID: 
25164588
35. How to develop and implement a national drug policy. Geneva: World 
Health Organization; 1988.
